HueDx, Inc: H-1B salaries and sponsorship
HueDx, Inc filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 4. Median offered salary: $105,530.
Does HueDx, Inc sponsor H-1B visas?
HueDx, Inc filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Mar 20, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Biomedical Research Engineer II | 1 | $80,059 |
| Head of R&D | 1 | $131,000 |
| Biomedical Research Engineer I | 1 | $75,982 |
| Chief Scientific Officer | 1 | $163,000 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 1 | $80,059 |
| FY2025 | 2 | $103,491 |
| FY2026 | 1 | $163,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Chief Scientific Officer | $163,000 Level II | Philadelphia, PA | Mar 20, 2026 | Apr 8, 2026 | Certified |
| Head of R&D | $131,000 Level IV | Philadelphia, PA | May 29, 2025 | Jun 3, 2025 | Certified |
| Biomedical Research Engineer I | $75,982 Level I | Philadelphia, PA | May 13, 2025 | Oct 1, 2025 | Certified |
| Biomedical Research Engineer II | $80,059 Level II | Philadelphia, PA | Jun 10, 2024 | Oct 1, 2024 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).